Literature DB >> 10356316

Late infantile neuronal ceroid lipofuscinosis is due to splicing mutations in the CLN2 gene.

J M Hartikainen1, W Ju, K E Wisniewski, D N Moroziewicz, A L Kaczmarski, L McLendon, D Zhong, C T Suarez, W T Brown, N Zhong.   

Abstract

Late infantile neuronal ceroid lipofuscinosis, LINCL, is one of the most common pediatric neurodegenerative disorders. It is caused by mutations in the CLN2 gene, which encodes a lysosomal pepstatin-insensitive peptidase (LPIP). We have identified a novel mutation, T523-1G --> A, by molecular analyses of three unrelated LINCL cases. The mutation was found to affect a 3' intronic splicing acceptor site, resulting in an aberrant mRNA with an insertion of 146 bp of intronic sequence. This causes a frame shift, produces a nonfunctional truncated protein, and results in LINCL. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356316     DOI: 10.1006/mgme.1999.2853

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  6 in total

Review 1.  Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.

Authors:  Sara E Mole; Ruth E Williams; Hans H Goebel
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

2.  Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.

Authors:  Romina Kohan; María Noelia Carabelos; Winnie Xin; Katherine Sims; Norberto Guelbert; Inés Adriana Cismondi; Patricia Pons; Graciela Irene Alonso; Mónica Troncoso; Scarlet Witting; David A Pearce; Raquel Dodelson de Kremer; Ana María Oller-Ramírez; Inés Noher de Halac
Journal:  Gene       Date:  2012-12-22       Impact factor: 3.688

3.  Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.

Authors:  Emily Gardner; Mitch Bailey; Angela Schulz; Mikel Aristorena; Nicole Miller; Sara E Mole
Journal:  Hum Mutat       Date:  2019-07-26       Impact factor: 4.878

4.  Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.

Authors:  Eva Wibbeler; Raymond Wang; Emily de Los Reyes; Nicola Specchio; Paul Gissen; Norberto Guelbert; Miriam Nickel; Christoph Schwering; Lenora Lehwald; Marina Trivisano; Laura Lee; Gianni Amato; Jessica Cohen-Pfeffer; Renée Shediac; Fernanda Leal-Pardinas; Angela Schulz
Journal:  J Child Neurol       Date:  2020-12-23       Impact factor: 1.987

5.  Case report: Analysis of novel compound heterozygous TPP1 variants in a Chinese patient with neuronal ceroid lipofuscinosis type 2.

Authors:  Sui-Bing Miao; Hui Guo; De-Xian Kong; Yuan-Yuan Zhao; Shu-Hong Pan; Yan Jiang; Xing Gao; Xiao-Hua Wu
Journal:  Front Genet       Date:  2022-08-31       Impact factor: 4.772

6.  Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency.

Authors:  Milan Elleder; Lenka Dvoráková; Larisa Stolnaja; Hana Vlásková; Helena Hůlková; Rastislav Druga; Helena Poupetová; Eva Kostálová; Josef Mikulástík
Journal:  Acta Neuropathol       Date:  2008-02-19       Impact factor: 15.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.